RET (R813Q)
Sign in to save this workspaceRET · Variant type: point · HGVS: p.R813Q
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Entrectinib | 100.0% | 0.0% | 93.69 |
| 2 | Pralsetinib | 100.0% | 0.0% | 93.43 |
| 3 | Selpercatinib | 99.8% | 0.2% | 96.72 |
| 4 | Tivozanib | 99.4% | 0.6% | 92.42 |
| 5 | Erdafitinib | 99.1% | 0.9% | 95.71 |
| 6 | Fedratinib | 98.9% | 1.1% | 96.21 |
| 7 | Alpelisib | 98.9% | 1.1% | 97.22 |
| 8 | Gilteritinib | 98.7% | 1.3% | 88.97 |
| 9 | Tenalisib | 98.7% | 1.3% | 97.98 |
| 10 | Repotrectinib | 98.3% | 1.7% | 84.21 |
| 11 | Sunitinib | 98.3% | 1.7% | 91.73 |
| 12 | Ripretinib | 97.5% | 2.5% | 92.95 |
| 13 | Futibatinib | 97.3% | 2.7% | 98.48 |
| 14 | Quizartinib | 96.9% | 3.1% | 99.50 |
| 15 | Vandetanib | 96.8% | 3.2% | 95.74 |
| 16 | Nintedanib | 96.0% | 4.0% | 90.23 |
| 17 | Apatinib | 95.7% | 4.3% | 97.73 |
| 18 | Ponatinib | 95.2% | 4.8% | 78.23 |
| 19 | Brigatinib | 94.8% | 5.2% | 82.96 |
| 20 | Regorafenib | 93.8% | 6.2% | 95.99 |
| 21 | Alectinib | 93.8% | 6.2% | 95.49 |
| 22 | Cabozantinib | 93.5% | 6.5% | 92.73 |
| 23 | Lenvatinib | 93.2% | 6.8% | 97.74 |
| 24 | Sorafenib | 91.6% | 8.4% | 96.72 |
| 25 | Avapritinib | 88.9% | 11.1% | 97.73 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Entrectinib | 100.0% | 99.6% | +0.4% |
| Pralsetinib | 100.0% | 100.0% | +0.0% |
| Selpercatinib | 99.8% | 100.0% | -0.2% |
| Tivozanib | 99.4% | 99.7% | -0.3% |
| Erdafitinib | 99.1% | 94.7% | +4.5% |
| Fedratinib | 98.9% | 99.9% | -1.0% |
| Alpelisib | 98.9% | 99.6% | -0.7% |
| Gilteritinib | 98.7% | 100.0% | -1.3% |
| Tenalisib | 98.7% | 98.5% | +0.2% |
| Repotrectinib | 98.3% | — | — |
| Sunitinib | 98.3% | 97.2% | +1.1% |
| Ripretinib | 97.5% | — | — |
| Futibatinib | 97.3% | 97.7% | -0.4% |
| Quizartinib | 96.9% | — | — |
| Vandetanib | 96.8% | 98.6% | -1.8% |
| Nintedanib | 96.0% | 100.0% | -4.0% |
| Apatinib | 95.7% | — | — |
| Ponatinib | 95.2% | 100.0% | -4.8% |
| Brigatinib | 94.8% | 94.9% | -0.1% |
| Regorafenib | 93.8% | 98.7% | -4.9% |
| Alectinib | 93.8% | 97.8% | -4.0% |
| Cabozantinib | 93.5% | 97.5% | -4.0% |
| Lenvatinib | 93.2% | 98.8% | -5.7% |
| Sorafenib | 91.6% | 94.0% | -2.4% |
| Avapritinib | 88.9% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_thyroid | Thyroid | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 12.7ms